2023 World Conference on Lung Cancer (Posters)-EP04.01. True Abnormal Cells in Normal Cases Detected by the PneuVision Test for Early-Stage Lung Cancer

EP04.01. True Abnormal Cells in Normal Cases Detected by the PneuVision Test for Early-Stage Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

The PneuVision test, developed to detect early-stage lung cancer, uses sputum and the Cell-CT platform to analyze cells in 3D with high resolution. Machine-learning classifiers were trained to detect abnormal cells, and cytologists confirmed positive tests. The test's accuracy, sensitivity, and cancer detection rate were high. The focus of this study was on the rate of positive tests in normal patients. The study included patients without diseases and patients with COPD or emphysema. The results showed that abnormal cells were not detected in normal cases without diseases, demonstrating the robustness and stability of the Cell-CT classification and cytology processes. However, abnormal cells were detected in normal cases with COPD and emphysema, indicating that these cells were from pre-cancer lesions. The PneuVision test demonstrated nearly perfect specificity, and abnormal cell detection in cases with COPD and emphysema was attributed to pre-cancer lesions. This study highlights the effectiveness of the PneuVision test in detecting early-stage lung cancer.<br /><br />Keywords: NSCLC, detection, specificity<br /><br />This research falls under the Screening and Early Detection track of the conference.

Asset Subtitle

Michael Meyer

Meta Tag

Speaker Michael Meyer

Topic Screening & Early Detection: Biomarkers/Imaging Technology

Keywords

PneuVision test

lung cancer detection

sputum analysis

Cell-CT platform

3D cell analysis

machine-learning classifiers

cytology process

positive tests

COPD and emphysema

pre-cancer lesions